Literature DB >> 10023636

Cardiovascular complications in patients with primary aldosteronism.

M Nishimura1, T Uzu, T Fujii, S Kuroda, S Nakamura, T Inenaga, G Kimura.   

Abstract

Primary aldosteronism (PA) is widely believed to be a relatively benign form of hypertension associated with a low incidence of vascular complications. However, several recent studies showed that cardiovascular complications were not rare in PA. PA is known as one of the most typical forms of sodium-sensitive hypertension. Recently, we found that the sodium sensitivity of blood pressure was a marker for greater risk for cardiovascular complications, especially stroke, in patients with essential hypertension. Therefore, we investigated cardiovascular complications in 58 patients with PA confirmed to be Conn's adenoma. Cardiovascular complications were found in 34% of 58 patients. Coronary artery disease was found in only one patient (1.7%), as angina pectoris. Stroke was found in nine patients (15.5%), four patients (6.9%) with cerebral infarctions and five patients (8.6%) with cerebral hemorrhages. Proteinuria and renal insufficiency were found in 14 (24.1%) and 4 (6.9%) patients, respectively. The incidence of cerebral infarction and renal insufficiency was greater in men than women. The prevalence of proteinuria was greater in patients with than without stroke (P = 0.03) among those aged older than 40 years. These results indicated that cardiovascular complications, especially stroke and proteinuria, were common in patients with PA, and proteinuria might be an indicator for stroke as target-organ damage.

Entities:  

Mesh:

Year:  1999        PMID: 10023636     DOI: 10.1016/s0272-6386(99)70298-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  36 in total

Review 1.  Aldosterone as a determinant of cardiovascular and renal dysfunction.

Authors:  M Epstein
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 2.  Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

Review 3.  Diagnosis and surgical management for primary hyperaldosteronism.

Authors:  Ravi Munver; Jennifer Yates
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

4.  Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease.

Authors:  Wei-Guo Chen; Ting-Ting Zhou; Peng Zhou; Xiao-Wei Li; Zhun Wu; Kai-Yan Zhang; Jin-Chun Xing
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 5.  Aldosterone and diabetic kidney disease.

Authors:  Young Sun Kang; Dae Ryong Cha
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

Review 6.  A comprehensive review of the clinical aspects of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

7.  Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study.

Authors:  Krishna Gaddam; Cecilia Corros; Eduardo Pimenta; Mustafa Ahmed; Thomas Denney; Inmaculada Aban; Seidu Inusah; Himanshu Gupta; Steven G Lloyd; Suzanne Oparil; Ahsan Husain; Louis J Dell'Italia; David A Calhoun
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

8.  Gene expression changes in the retina after systemic administration of aldosterone.

Authors:  Aoi Ono; Kazuyuki Hirooka; Yuki Nakano; Eri Nitta; Akira Nishiyama; Akitaka Tsujikawa
Journal:  Jpn J Ophthalmol       Date:  2018-04-30       Impact factor: 2.447

Review 9.  Aldosterone: a risk factor for vascular disease.

Authors:  Mario Fritsch Neves; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

10.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.